Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programsGoogle Miscellanea

INDIANAPOLIS, Oct. 7, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced additional details on its SARS-CoV-2 neutralizing antibody programs – including interim data on combination therapy in recently diagnosed patients with mild-to-moderate COVID-19 – and plans to make these therapies broadly available to patients. “Our teams have worked tirelessly the last seven months […]